Navigation Links
Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
Date:6/9/2009

WOODCLIFF LAKE, N.J., June 9 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon nasal spray is a generic version of Novartis' Miacalcin(R). Annual U.S. sales of Miacalcin were approximately $112 million in 2008, according to IMS Health data.

Important information about calcitonin-salmon nasal spray

Calcitonin-salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years post menopause with low bone mass relative to healthy premenopausal females.

Calcitonin-salmon nasal spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated.

Because Calcitonin is a polypeptide, the possibility of a systemic allergic reaction exists.

Please read full prescribing information available at www.parpharm.com/products.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
2. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
3. Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference
4. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications
7. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
8. Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs
9. Isis Pharmaceuticals to Present at Goldman Sachs 30th Annual Global Healthcare Conference
10. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
11. ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Those who ... center can find some useful information in a new video released by Serenity ... video, which can be viewed on the Serenity Recovery YouTube channel, examines various ...
(Date:5/2/2016)... ... 2016 , ... As directed by its board of directors during its April ... to allow certified nurse practitioners (CNP) to practice to the full scope of their ... for three years and 3,600 hours. , In addition, HAP supports CNPs who are ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Civilian Corps of ... honor the civilian nurses that care for its uniformed service members, the retired service ... in 1974 designating May 6th through May 12th National Nurses Week. It acknowledges the ...
(Date:5/2/2016)... ... 2016 , ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident ... recently at the Annual Meeting in Los Angeles. The first annual art forum was ... Annual Meeting attendees. , “Through art I hope to educate people about radiology ...
(Date:5/2/2016)... ... May 02, 2016 , ... WestHarbor Growth Partners, a growth, ... release of Grow Healthy Vending’s newly revamped brand campaign. Grow Healthy Vending ... vending providers in North America with locations across the United States as well ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... company, today announced data from the first cohort ... clinical trial (the OVATION Study) combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  In the first three ...
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
Breaking Medicine Technology: